Bio-Rad gets new DNA sequencing offering with GnuBIO buy
This article was originally published in Clinica
Executive Summary
Life sciences research and clinical diagnostic specialist Bio-Rad Laboratories has moved into the DNA sequencing sector, purchasing GnuBIO for an undisclosed fee. The privately-held Cambridge, Massachusetts firm has developed a “faster and fully integrated” droplet-based sequencing technology that produces results in a few hours instead of days, according to the company, and can be used in medical diagnostics as well as research markets. According to GnuBIO’s website: “Whereas other sequencing technologies require separate workflows for target selection, DNA amplification, DNA sequencing and analysis, the GnuBIO technology integrates the entire workflow into a single, low-cost instrument.” Jefferies analyst Brandon Couillard said he was "disappointed to see another early-stage dilutive acquisition," estimating that it would hit Bio-Rad to the tune of around $20m per year. However, the analyst added: "While Bio-Rad's foray into next-generation sequencing makes us somewhat skittish, [it] is clearly investing for future market developments and its stellar acquisition track record has earned it the benefit of the doubt here." He concluded: "We expect Bio-Rad to bring significant technical & commercial know-how to GnuBIO, owing to its well-established presence in droplet digital PCR with QuantaLife."
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.